News

AstraZeneca and Ionis Pharmaceuticals have closed a previously announced commercialisation agreement to develop and market experimental therapy, eplontersen, previously called IONIS-TTR-LRX. The deal was announced earlier this month.

The move comes after the Drugs Controller General of India (DCGI) granted emergency use authorization (EUA) for the vaccine, dubbed ‘The World’s COVID-19 Vaccine’. Corbevax technology was engineered

Keytruda is Merck’s an anti-programmed death receptor-1 (PD-1) therapy that hinders the interaction between PD-1 and its ligands, PD-L1 and PD-L2. It increases the ability of the body’s

The acquisition of 3DBT for the consideration amount is to be satisfied by the issuance to the sellers of a total of 33,900,003 consideration shares at 7.37 pence

A fully human biologic, Cosentyx is developed to directly target interleukin-17A (IL-17A), a cytokine. IL-17A is involved in the inflammation of plaque psoriasis, psoriatic arthritis (PsA), ankylosing spondylitis

Trastuzumab is a monoclonal antibody intended to treat human epidermal growth factor receptor 2 positive (HER2-positive) breast and metastatic gastric cancers. The company aims to secure EMA approval

The agreement with the Government of the UK is subject to the local authorisation of the Covid-19 pill. Previously, the UK placed an order of 250,000 Paxlovid doses.

Molnupiravir is an orally administered form of a potent ribonucleoside analogue that blocks the SARS-CoV-2 replication. It is planned to be sold under the trademark Lagevrio in the

This brings the company’s total Series A funding raised to $107m. The financing was led by Third Rock Ventures and saw participation from Smilegate Investment, Schroders Capital, Alexandria